

GENETIC TEST:
Dihydropyrimidine dehydrogenase deficiency (5-fluorouracil (5-FU) toxicity) - Pharmacogenetics

FULL NAME:	Dihydropyrimidine dehydrogenase deficiency (5-fluorouracil (5-FU) toxicity) - Pharmacogenetics
DESCRIPTION:	DPYD genotyping (4 hot spot variants (c.1679T>G (DPYD*13), c.1905+1G>A (IVS14+1G>A - DPYD*2A) et c.2846A>T(D949V, rs67376798) and c.1236G>A (HapB3, rs56038477)).
TEST TYPE:	Clinical
TEST SPECIALTY:	Molecular Genetics
TEST PURPOSE:	Drug Response
SPECIMEN:	Peripheral (whole) blood on EDTA
METHOD CATEGORY:	Mutation screening
METHOD TECHNIQUE:	PCR based technique
RIZIV CODE:	565390-565401
ACCREDITATION (ISO 15189):	2022-02-24 / 2026-02-23

EQA:	• DPYD (Pharmacogenetics PGX3), • pharmacogenetic panel
TURNAROUND TIME (MAXIMUM):	5 days
CREATED:	25 Jul 2019 - 17:27
CHANGED:	16 Jan 2024 - 13:26
URL:	https://www.chuliege.be/jcms/c_6963510/fr/etude-du-gene-dpyd-toxicite-du-5-fu

Source URL: http://gentest.healthdata.be/genetic_test/882

RELATED CONTENT

Related Diseases

- [5-fluorouracil toxicity](#)
- [Dihydropyrimidine dehydrogenase deficiency](#)

Related Laboratories

- [Centre de Génétique Humaine - CHU Sart-Tilman](#)

Related Analytes

- [dihydropyrimidine dehydrogenase](#)

Source URL: http://gentest.healthdata.be/genetic_test/882